Evolus, Inc.

Good afternoon, everyone, and thank you for standing by. Welcome to Evalyst's second quarter 2026 earnings call. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, today's conference call is being recorded and webcast live. All participants are in a listen-only mode. After the speaker's remarks, there will be a question and answer session. I would now like to turn the conference over to Nareg Sagherian, Vice President and Head of Global Vestor Relations in Corporate Communications. Please go ahead.

Thank you, Operator, and welcome to everyone joining us on today's call to review Evelus' second quarter financial results. Our second quarter press release is now available on the Investor Relations section of our website at evelus.com. Joining me on today's call are David Moatazedi, President and Chief Executive Officer, Rui Avelar, Chief Medical Officer and Head of R&D, and Tatjana Mitchell, Chief Financial Officer. Today's call will include forward-looking statements. Actual results may differ materially due to risks and uncertainties outlined in our earnings press release and SEC filings. These forward-looking statements are based on current assumptions, and we undertake no obligation to update them. Additionally, we will discuss certain non-GAAP financial measures. These measures should be considered in addition to and not as a substitute for our GAAP results. A reconciliation of GAAP to non-GAAP measures is included in today's earnings release. As a reminder, our earnings release and SEC filings are available on the SEC's website and on our Investor Relations website. Following the conclusion of today's call, a replay will be available on our website at investors.evalus.com. With that, I'll turn the call over to our CEO, David Moatazedi.

Thank you, Nareg, and good afternoon, everyone. The second quarter represents a meaningful inflection point for Avalos. We delivered 21% revenue growth, generated our third consecutive quarter of positive adjusted EBITDA, expanded our international footprint with the launch of Esteem in Europe, and announced two strategic licensing agreements that further strengthen our long-term portfolio. Importantly, Evelus gained significant share across the U.S. injectable aesthetics market during the quarter, undergoing the growing momentum of our portfolio strategy across both neurotoxins and hyaluronic acid gels. Reflecting the strength of our first-half performance, we also raised our full-year 2026 financial outlook. As we enter the second half of the year, we are well-positioned to build on this momentum. Consumer demand continued to strengthen during the quarter. Treatment intervals remained stable, and practitioners reported healthy patient traffic and engagement. We estimate the U.S. neurotoxin market grew at a faster-than-expected mid-single-digit growth rate during the quarter, while the hyaluronic acid gel market returned a positive growth following two consecutive years of declines. Consumers continued to prioritize aesthetic treatments, and practices remain focused on products that deliver predictable clinical outcomes and high patient satisfaction. Against this improving backdrop, we continue to meaningfully outpace the market through disciplined commercial execution, which led to market share gains across our portfolio. That execution is evident through our business performance. Global toxin revenue exceeded 75 million during the quarter, driven by double-digit toxin growth across both the United States and our international markets. As our portfolio continues to expand, we're seeing customers increasingly adopt our products within their practices. Our portfolio focus is delivering particularly strong results among accounts participating in our Avalos portfolio growth bundle. In the first six months since we debuted the program, Approximately 70% of these customers purchased Avelis, compared with approximately 25% penetration of Avelis across our overall customer base. Javeau continues to strengthen its competitive position through growing customer loyalty and market share gains, while Avelis is following the same disciplined commercialization strategy that made Javeau successful. During the quarter, Avelis revenue increased by more than $2 million sequentially, reflecting increased customer penetration, reorder rates, and utilization within existing accounts. Together, these trends reinforce our confidence that our portfolio focus is gaining traction, enabling us to increase share across both neurotoxins and injectable hyaluronic acid gels, while deepening customer relationships and expanding our share of wallets. As a result of the continued strength across our portfolio, we remain on track for both Evelis and our international business to each contribute more than 10% of total company revenue this year. A key milestone in our evolution is our recent partnership with IPSA to exclusively develop and commercialize Profilo in the United States. Profilo is an asset we've been actively pursuing because it represents a gold standard in the rapidly emerging skin quality category. With the addition of Profilo, Avelis is expanding into a new third injectable aesthetics vertical of skin quality, further diversifying our differentiated portfolio and reinforcing our strategy of building a comprehensive injectable platform. Profilo defines the skin quality category globally and is widely recognized as a market-leading brand for skin quality in Europe, with no directly comparable product currently available in the United States. Similar to GEVO, we will own the U.S. regulatory filings and lead the clinical development and commercialization strategy for Profilo, creating long-term value on the asset, which has the potential to generate more than $100 million in peak annual revenue. More broadly, Our partnerships with companies such as Ipsa, Cimetase, and Daewoong demonstrate that leading global innovators increasingly view Avelis as a partner of choice to develop and commercialize quality aesthetic products. Our proven execution, deep customer relationships, and expanding global platform position us to continue attracting high-quality assets from world-class partners as we build the next generation of injectable aesthetics. Our international business is also becoming an increasingly important contributor to our long-term strategy. During the quarter, we successfully launched the esteemed collection of injectable hyaluronic acid gels in Europe, where early customer response has been very encouraging. We also announced the expansion of our relationship with Cimetase to include Canada, Australia, and New Zealand. Strategically, this is an important milestone as we now hold exclusive rights to commercialize our injectable hyaluronic acid gel portfolio in every market where we maintain rights for Nuceva, while expanding our global addressable market by approximately $200 million annually. The combination of a broader portfolio and expanded geographical footprint make our international business an increasingly meaningful contributor to our long-term growth and revenue outlook. While we continue to invest in our long-term growth strategy, we remain disciplined in our financial execution. Our third consecutive quarter of positive adjusted EBITDA demonstrates that we can deliver profitable growth while funding the strategic initiatives that will drive the next phase of our evolution. Through the first six months of the year, we delivered 14% revenue growth ahead of the pace implied in our original guidance, giving us the confidence to raise our full year 2026 Financial Outlook. Our results this quarter reflect the strength of our expanding portfolio, the effectiveness of our commercial strategy, and the operating discipline of our team in executing against our long-term objectives. With that, I'd like to now turn the call over to Rui.